IA
Weds, April 22: Amneal Buys Kashiv, Roche Advances Fenebrutinib, and Merck Bets on AI
IA
BioBrief di BioBrief
Note sull'episodio
Today on BioBrief:
- Amneal moves into biosimilars with its Kashiv acquisition,
- Roche submits fenebrutinib for multiple sclerosis review, and
- Merck commits up to $1 billion to Google Cloud AI infrastructure.
Parole chiave
rochemerckgoogleaibiotechbiopharmapharmaamnealkashiv